564-25-0 Usage
Uses
Used in Antibacterial Applications:
Doxycycline is used as an antibiotic for treating a wide range of bacterial infections due to its broad-spectrum activity. It is particularly effective against gram-positive and gram-negative bacteria, as well as some protozoan parasites.
Used in Non-gonococcal Urethritis and Cervicitis Treatment:
Doxycycline is employed as a treatment for non-gonococcal urethritis and cervicitis, providing relief from symptoms and inhibiting the growth of causative bacteria.
Used in Chronic Obstructive Pulmonary Disease (COPD) Management:
Doxycycline is used to treat exacerbations of bronchitis in patients with chronic obstructive pulmonary disease (COPD), helping to reduce inflammation and control infection.
Used in Adult Periodontitis Treatment:
Doxycycline is utilized in the treatment of adult periodontitis, a severe gum infection that can lead to tooth loss and other complications. It helps to control bacterial growth and reduce inflammation in the affected areas.
Used in Uremic Patients with Infections Outside the Urinary Tract:
Due to its low renal clearance, doxycycline is preferred for uremic patients with infections outside the urinary tract, as it does not accumulate in patients with impaired renal function.
Used in Pharmaceutical Industry:
Doxycycline is used as a key ingredient in the development of various pharmaceutical products, particularly those targeting bacterial and protozoan infections.
Used in Research and Development:
Doxycycline is utilized in research and development for studying its effects on different organisms and exploring potential new applications in the medical field.
Chemical Properties:
Doxycycline is a yellow solid with chemical properties that contribute to its stability and effectiveness as an antibiotic.
Originator
Cyclidox,Protea,Australia
Indications
Doxycycline (Vibramycin, Monodox) has similar absorption and durationof-
activity characteristics. Its effectiveness in acne approaches that of minocycline,
when used in the same fashion with similar dosages. Early data suggests
that subantimicrobial doses of doxycycline, 20 mg (Periostat), may play a
therapeutic role in acne by reducing inflammation through anticollagenolytic,
antimatrix-degrading metalloproteinase, and cytokine downregulating properties.
Manufacturing Process
Hydrogen was introduced into a standard hydrogenation vessel containing 10
grams 6-deoxy-6-demethyl-6-methylene-5-oxytetracycline hydrochloride(methacycline), 150 ml methanol and 5 grams 5% rhodium on carbon. The
pressure was maintained at 50 psi while agitating at room temperature for 24
hours. The catalyst was then filtered off, the cake washed with methanol and
the combined filtrates were evaporated to dryness. The dry solids were
slurried in ether, filtered and the cake dried. The resulting solids exhibited a
bioactivity of 1,345 units per mg versus K. pneumoniae.Water (35 ml) was employed to dissolve 8.5 grams of the above product and
the pH was adjusted to 6.0 with triethylamine, sufficient dimethyl formamide
being added to maintain the solids in solution. Cellulose powder (2 kg) was
slurried in water-saturated ethyl acetate and packed into a tower of about 3?
inches diameter, to a height of 3 ft. The product solution was then
chromatographed over this column, developing with about 12 liters watersaturated ethyl acetate. The first product fraction to come from the tower
yielded 1.85 grams 6-epi-6-deoxy-5-oxytetracycline. The next fraction
contained 2.0 grams of 6-deoxy-6-demethyl-6-methylene-5-oxytetracycline.
The third fraction yielded 0.8 grams 6-deoxy-5-oxytetracycline.
Therapeutic Function
Antibiotic
Antimicrobial activity
It
is active against some tetracycline-resistant Staph. aureus and
is more active than other tetracyclines against Str. pyogenes,
enterococci and Nocardia spp. Mor. catarrhalis (MIC 0.5
mg/L), Legionella pneumophila and most strains of Ureaplasma
urealyticum (MIC 0.5 mg/L) are susceptible.
Pharmaceutical Applications
6-Deoxy-5β-hydroxytetracycline. A semisynthetic product
supplied as the hyclate, calcium salt or the hydrochloride for
oral and intravenous administration.
Pharmacokinetics
Oral absorption： 90%
Cmax 100–200 mg oral： 1.7–5.7 mg/L after 2–3.5 h
100 mg intravenous infusion (1 h)： 2.5 mg/L end infusion
Plasma half-life：18 h
Volume of distribution： 0.9–1.8 L/kg
Plasma protein binding： 90%
Absorption
Doxycycline is rapidly absorbed from the upper gastrointestinal
tract and absorption appears to be linearly related to the
administered dose. Food, especially dairy products, reduces
peak serum concentrations by 20%. Alcohol also delays
absorption. As with other tetracyclines, divalent and trivalent
cations, as in antacids and ferrous sulfate, form chelates
which reduce absorption.
Distribution
The greater lipophilicity of doxycycline is responsible for its
widespread tissue distribution. Concentrations in liver, biliary
system, kidneys and the digestive tract are approximately twice
those in plasma. Within the respiratory tract, it achieves concentrations
of 2.3–6.7 mg/kg in tonsils and 2.3–7.5 mg/kg in maxillary
sinus mucosa. In bronchial secretions concentrations
are about 20% of plasma levels, increasing to 25–35% in the presence
of pleurisy. Gallbladder concentrations are approximately
75% those of plasma, and prostate concentrations are 60–100%.
It penetrates well into the aqueous humor. CSF concentrations
range from 11% to 56% of plasma levels and are not affected by
inflammation. In the elderly, tissue concentrations are 50–100%
higher than in young adults. The half-life remains unaltered and
one explanation is reduced fecal elimination.
Metabolism and excretion
Doxycycline is largely excreted unchanged. Around 35% is
eliminated through the kidneys and the remainder through
the digestive tract. Renal clearance ranges from 1.8 to 2.1 L/h,
and is largely via glomerular filtration, with approximately
70% tubular reabsorption. Alkalinization enhances renal
clearance. Fecal elimination partly reflects biliary excretion
but also includes diffusion across the intestinal wall. Provided
the drug is not chelated, reabsorption occurs with enterohepatic
recycling. The elimination half-life is long (15–25 h).
The half-life and the area under the concentration–time
curve (AUC) are little altered in renal insufficiency, with no
evidence of accumulation after repeat dosing, even in anuric
patients, evidently as a result of increased clearance through
the liver or gastrointestinal tract, since biliary and fecal concentrations
increase in renal failure. Although the plasma elimination
half-life is unchanged, the drug appears to accumulate in
tissues with increasing renal failure, and it has been suggested
that less drug is bound to plasma protein and red cells through
competition with other metabolites, which in turn increases
hepatic elimination. Pharmacokinetics are unaltered by hemodialysis
or peritoneal dialysis. Clearance is decreased by about
half in patients with type IIa and type IV hyperlipidemia.
The plasma elimination half-life is shortened by various
antiepileptic agents including phenytoin, barbiturates and
carbamazepine, presumably as a result of liver enzyme induction,
although there is also evidence for some interference
with the protein binding of doxycycline.
Clinical Use
Its once-daily administration and safety in renal insufficiency
make it one of the most widely used tetracyclines. It is used
in the prophylaxis and treatment of malaria in areas in which
resistance to conventional antimalarial agents is common.
Clinical Use
Like the other tetracyclines, doxycycline inhibits the pathogen’s protein synthesisby reversibly inhibiting the 30S ribosomal subunit.Bacteria and Plasmodium ribosomal subunits differ significantlyfrom mammalian ribosomes such that this group ofantibiotics do not readily bind to mammalian ribosomesand, therefore, show good selective toxicity. Althoughdoxycycline is a good antibacterial, its use for malaria islimited to prophylaxis against strains of P. falciparumn resistantto chloroquine and sulfadoxine–pyrimethamine.This use normally should not exceed 4 months. Becausethe tetracyclines chelate calcium, they can interfere withdevelopment of the permanent teeth in children. Therefore,their use in children definitely should be short term. Also, tetracycline photosensitivity must be kept in mind, particularlybecause areas where malaria is endemic are also theareas with the greatest sunlight.
Side effects
Untoward reactions are generally those typical of the group
but gastrointestinal side effects are less common than with
other tetracyclines due to the lower total dosage and the ability
to administer the drug with meals. Esophageal ulceration
as a result of capsule impaction has been reported. Dental and
bone deposition appear to be less common than with other
tetracycline derivatives. Other adverse phenomena include
occasional vestibular toxicity.
Hypersensitivity reactions include photosensitivity and
eosinophilia, but rarely anaphylaxis. In common with demeclocycline
and chlortetracycline it may be a more powerful
sensitizer than other tetracyclines. It is contraindicated in
patients with acute porphyria because it has been demonstrated
to be porphyrinogenic in animals.
Synthesis
Doxycycline, 4-dimethylamino-1,4,4a,5,5a,6,11,12a-oxtahydro-3,5,10,12, 12a-pentahydroxy-6-methyl-1,11-dioxo-2,naphthacencarboxamide (32.3.7), is an isomer of tetracycline that differs only in the placement of one hydroxyl group. Doxycycline can be formally viewed as the result of transferring the C6 hydroxyl group of tetracycline to C5. Doxycycline is synthesized in two different ways from oxytetracycline (32.3.2). One of the ways suggests dehydrating oxytetracycline at C6 by reducing the tertiary hydroxyl group with hydrogen using a rhodium on carbon catalyst.
The second way is analogous to that of giving methacycline, which suggests an oxidation stage of the homoallyl system, except that N-chlorosuccinimide is used as the oxidant, which results in the formation of a naphthacentetrahydrofuran derivative (32.3.8), and which upon being reacted with hydrofluoric acid breaks apart to form an 11a-chloro- 6-exomethylene derivative (32.3.9). Reductive dechlorination of this product using sodium thiosulfate forms the intermediate methacycline (32.3.6), and thiophenol is joined to the methyl group that carry out radical reactions, forming the derivative (32.3.10). This product is reduced by hydrogen over a Raney nickel catalyst, during which reductive desulfurization takes places, giving doxycycline.
Drug interactions
Potentially hazardous interactions with other drugsAnticoagulants: possibly enhanced anticoagulant
effect of coumarins and phenindione.Ciclosporin: possibly increases plasma-ciclosporin concentration.Oestrogens: possibly reduced contraceptive effects of
oestrogens (risk probably small)
Retinoids: possible increased risk of benign
intracranial hypertension - avoid.
Metabolism
Doxycycline is well absorbed on oral administration (90–100% when fasting; reduced by
20% by co-consumption with food or milk), has a half-life permitting once-a-day dosing for mild infections,
and is excreted partly in the feces and partly in the urine.
Dosage forms
50 mg b.i.d. to q.i.d.; 100 mg q.d. to b.i.d. Recent evidence suggest
that sub-antimicrobial dose of 20 mg b.i.d. is also effective. No dosage
adjustments needed for renal impairment.
Check Digit Verification of cas no
The CAS Registry Mumber 564-25-0 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 5,6 and 4 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 564-25:
(5*5)+(4*6)+(3*4)+(2*2)+(1*5)=70
70 % 10 = 0
So 564-25-0 is a valid CAS Registry Number.
InChI:InChI=1/C22H24N2O8/c1-7-8-5-4-6-9(25)11(8)16(26)12-10(7)17(27)14-15(24(2)3)18(28)13(21(23)31)20(30)22(14,32)19(12)29/h4-7,10,14-15,17,25,27-29,32H,1-3H3,(H2,23,31)/t7-,10+,14+,15-,17-,22-/m0/s1
564-25-0Relevant articles and documents
PENTACYCLINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS
-
Paragraph 0058; 0218-0219; 0251; 0258-0259, (2020/07/02)
The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among many organisms previously susceptible to tetracycline antibiotics. The modular synthesis of tetracyclines and tetracycline analogs described provides an efficient and enantioselective route to a variety of tetracycline analogs and polycyclines previously inaccessible via earlier tetra-cycline syntheses and semi-synthetic methods. These analogs may be used as anti-microbial agents or anti-pro liferative agents in the treatment of diseases of humans or other animals.
Preparation method of doxycycline hydrochloride intermediate hydride
-
Paragraph 0026; 0029; 0031; 0034, (2017/07/19)
The invention discloses a preparation method of a doxycycline hydrochloride intermediate hydride. The preparation method comprises adding dried oxytetracycline chloride into a dehydration pot containing HF, carrying out reaction dehydration, carrying out standing, evaporating and concentrating to remove HF, collecting the concentrated solution through methanol, neutralizing the methanol solution containing the concentrated solution through calcium hydroxide or calcium oxide powder, carrying out a hydrogenation reaction process on the neutralized methanol solution in the presence of a Pd/C catalyst and an inhibitor, filtering the reaction product, and carrying out a salt formation reaction process on the filtrate and a sulfonyl salicylate methanol solution to obtain the doxycycline hydrochloride intermediate hydride. The preparation method is free of p-toluenesulfonic acid, has simple processes, can be operated easily and greatly reduces a production cost.
Solid state chemistry of the antibiotic doxycycline: Structure of the neutral monohydrate and insights into its poor water solubility
Legendre, Alexandre O.,Silva, Laila R. R.,Silva, Douglas M.,Rosa, Iara M. L.,Azarias, Lilian C.,De Abreu, Polyana J.,De Araujo, Magali B.,Neves, Person P.,Torres, Claudia,Martins, Felipe T.,Doriguetto, Antonio C.
experimental part, p. 2532 - 2540 (2012/07/28)
The active pharmaceutical ingredient (API) doxycycline (DOX) is a broad-spectrum antibiotic mainly used in the treatment of respiratory and urinary tract infections and, like many drugs, its efficacy may be affected by the crystal form. Up to now, only the crystal structure of doxycycline hyclate (DOX·HYC) (generic name of brand names such as DORYX, PERIOSTAT, ATRIDOX, and VIBRAMYCIN) has been reported. This study presents the single-crystal X-ray diffractometry structural characterisation of another crystal form, doxycycline monohydrate (DOX·H2O) (generic name of brand names such as MONODOX and ORACEA). The DOX·H2O structure was compared with the known DOX·HYC one in terms of intra- and intermolecular geometries, and their melting temperature, water solubility and dissolution rate were measured. These data allowed us to establish relationships between solid state properties related to the pharmaceutical performance of the two DOX crystal variants and their supramolecular structures for the first time. Both hyclate and monohydrate forms crystallise the DOX molecules as zwitterions in which their dimethylamine groups are protonated and one of their hydroxyl groups is deprotonated. Whereas two conformers were observed in the DOX·HYC (i.e., the amine group is next to the enolate in one of them (T1) and beside the carbonyl in the other one (T2)), only one (T2) was found in DOX·H2O. Additionally, in the hyclate form, the presence of ethanol in the crystal lattice could be related to a rotation around the C-C bond of the amide group, directing the oxygen toward the amine group in one (T1) of the two conformers present in this solid state phase. Meanwhile, in the other crystallographically independent molecule (T2), the amide nitrogen is on the same side as the amine. However, only the conformer similar to T1 in DOX·HYC was observed in DOX·H2O. The crystal packing of DOX·H2O was stabilised by several intermolecular hydrogen bonds, with each drug entity interacting with another two DOX and three water molecules in such a way that a compact supramolecular network was formed. This structure was saturated in terms of hydrogen bonding, which could be related to its lower solubility and dissolution rate relative to DOX·HYC. The Royal Society of Chemistry 2012.
A robust platform for the synthesis of new tetracycline antibiotics
Sun, Cuixiang,Wang, Qiu,Brubaker, Jason D.,Wright, Peter M.,Lerner, Christian D.,Noson, Kevin,Charest, Mark,Siegel, Dionicio R.,Wang, Yi-Ming,Myers, Andrew G.
supporting information; experimental part, p. 17913 - 17927 (2009/07/18)
Tetracyclines and tetracycline analogues are prepared by a convergent, single-step Michael-Claisen condensation of AB precursor 1 or 2 with D-ring precursors of wide structural variability, followed by removal of protective groups (typically in two steps). A number of procedural variants of the key C-ring-forming reaction are illustrated in multiple examples. These include stepwise deprotonation of a D-ring precursor followed by addition of 1 or 2, in situ deprotonation of a D-ring precursor in mixture with 1 or 2, and in situ lithium-halogen exchange of a benzylic bromide D-ring precursor in the presence of 1 or 2, followed by warming. The AB plus D strategy for tetracycline synthesis by C-ring construction is shown to be robust across a range of different carbocyclic and heterocyclic D-ring precursors, proceeding reliably and with a high degree of stereochemical control. Evidence suggests that Michael addition of the benzylic anion derived from a given D-ring precursor to enones 1 or 2 is quite rapid at -78 °C, while Claisen cyclization of the enolate produced is rate-determining, typically occurring upon warming to 0 °C. The AB plus D coupling strategy is also shown to be useful for the construction of tetracycline precursors that are diversifiable by latter-stage transformations, subsequent to cyclization to form the C ring. Results of antibacterial assays and preliminary data obtained from a murine septicemia model show that many of the novel tetracyclines synthesized have potent antibiotic activities, both in bacterial cell culture and in vivo. The platform for tetracycline synthesis described gives access to a broad range of molecules that would be inaccessible by semisynthetic methods (presently the only means of tetracycline production) and provides a powerful engine for the discovery and, perhaps, development of new tetracycline antibiotics.
SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF
-
Page/Page column 117-118, (2008/06/13)
The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among many organisms previously susceptible to tetracycline antibiotics. The modular synthesis of tetracyclines and tetracycline analogs described provides an efficient and enantioselective route to a variety of tetracycline analogs and polycyclines previously inaccessible via earlier tetracycline syntheses and semi-synthetic methods. These analogs may be used as anti-microbial agents or anti-proliferative agents in the treatment of diseases of humans or other animals.
Ligand effects in the hydrogenation of methacycline to doxycycline and epi-doxycycline catalysed by rhodium complexes molecular structure of the key catalyst [closo-3,3-(η2,3-c7h7ch2)-3,1,2-rhc2b9h11]
Felekidis,Goblet-Stachow,Liegeois,Pirotte,Delarge,Demonceau,Fontaine,Noels,Chizhevsky,Zinevich,Bregadze,Dolgushin,Yanovsky,Struchkov
, p. 405 - 412 (2007/10/03)
The catalytic reduction of the exocyclic methylene group of methacycline (A) leads to the formation of two diastereoisomers, doxycycline (B, the α-epimer) and 6-epi-doxycycline (C, the β-epimer), with a selectivity which markedly depends on the nature of hydrocarbon and carborane ligands of closo-(π-cyclodienyl)rhodacarborane catalysts. Neutral norbornadienyl complexes with unsubstituted carborane ligands [closo-3,3-(η2,3-C7H7CH2)-3,1,2-RhC2B9H11] (1) and [closo-2,2-(η2,3-C7H7CH2)-2,1,7-RhC2B9H11] (7) are more active and afford higher selectivity in the formation of doxycycline than those having mono-or di-substituents at the carborane cage, [closo-3,3-(cyclodienyl)-1-R-2-R′-3,1,2-RhC2B9H9] (R = H, R′ = Me, PhCH2; R = R′ = Me; cyclodienyl = η2,3-C7H7CH2 or η-C10H13) as well as those from the closely related series of η5-cyclopentadienyl complexes [(η2,3-C7H7CH2)Rh(η5-C5Rn)]+PF-6 (Rn = H5, Me5, or H2-1,2,4-Ph3). Mechanistic aspects of the hydrogenation reaction of methacycline are sketched. The results of the X-ray diffraction study of the best catalyst 1 are reported.
Stereoselective Hydrogenation of Methacycline to Doxycycline Catalysed by Rhodium-Carborane Complexes
Pirotte, B.,Felekidis, A.,Fontaine, M.,Demonceau, A.,Noels, A. F.,et al.
, p. 1471 - 1474 (2007/10/02)
Doxycycline (2), a tetracycline antibiotic extensively used in chemotherapy, was obtained stereoselectively from the hydrogenation of methacycline (1), catalysed by novel rhodium-carborane complexes. Key words: stereoselective hydrogenation; rhodium; carborane; methacycline; doxycycline
